Lucid Diagnostics Inc (NASDAQ:LUCD) currently has a daily average trading volume of 987.10K but it saw 1903713 shares traded in last market. With a market cap of 140.16M USD, the company’s current market price of $1.33 came rising about 3.10 while comparing to the previous closing price of $1.29. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.80 and as low as $0.63. In the recent trading on the day, stock has struck highest price mark of $1.2705 while lowest mark touched by it was $1.36.
Taking a look at 20-day trading activity of Lucid Diagnostics Inc (LUCD) gives us an average price of $1.3725, while its current price level is -26.11% below from 52-week high level whereas it is 111.08% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.4037 while that of 200 days or SMA-200 reads an average of $0.9986. A closer look into the stock’s movement over the week reveals that its volatility is standing at 7.64% during that period while stretching the period over a month that increases to 8.89%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 49.48 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Ascendiant Capital Markets which initiated the stock as “Buy” in its note to investors issued on December 27, 2021, recommending a price target of $16 for it. Cantor Fitzgerald also issued its recommendations for the stock as it initiated the price target for the stock is $21.
Over the week, LUCD’s stock price is moving 22.02% up while it is -14.19% when we observe its performance for the past one month. Year-to-date it is 62.45% up and over the past year, the stock is showing an upside performance of 77.14%.
The company is expected to be releasing its next quarterly report on 2025-Mar-23, for which analysts forecasted an EPS of -0.11 while estimate for next year EPS is -0.4. In next quarter, company is expected to be making quarterly sales of $1.54M as analysts are expecting the sales for current fiscal year at $8.54M and seeing the company making $26.11M in sales next year. Moreover, analysts are in estimates of $1.28M for current-quarter revenue.
Currently, Lucid Diagnostics Inc’s total number of outstanding shares is 63.07M with 35.95% of that held by the insiders while 4.46% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -737.38% and return on equity (ROE) at -2956.43%. Stock’s beta reads 1.28. Stock has a price to sale or P/S ratio amounts to 32.22. Its return on asset (ROA) is -157.04% on average.
